Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort
- PMID: 21924545
- DOI: 10.1016/j.eururo.2011.08.042
Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort
Abstract
Background: Accurate pretreatment assessment of prostate cancer (PCa) aggressiveness is important in decision making. Gleason grade is a critical predictor of the aggressiveness of PCa. Transrectal ultrasound-guided biopsies (TRUSBxs) show substantial undergrading of Gleason grades found after radical prostatectomy (RP). Diffusion-weighted magnetic resonance imaging (MRI) has been shown to be a biomarker of tumour aggressiveness.
Objective: To improve pretreatment assessment of PCa aggressiveness, this study prospectively evaluated MRI-guided prostate biopsies (MR-GBs) of abnormalities determined on diffusion-weighted imaging (DWI) apparent diffusion coefficient (ADC) maps. The results were compared with a 10-core TRUSBx cohort. RP findings served as the gold standard.
Design, setting, and participants: A 10-core TRUSBx (n=64) or MR-GB (n=34) was used for PCa diagnosis before RP in 98 patients.
Measurements: Using multiparametric 3-T MRI: T2-weighted, dynamic contrast-enhanced imaging, and DWI were performed to identify tumour-suspicious regions in patients with a negative TRUSBx. The regions with the highest restriction on ADC maps within the suspicions regions were used to direct MR-GB. A 10-core TRUSBx was used in a matched cohort. Following RP, the highest Gleason grades (HGGs) in biopsies and RP specimens were identified. Biopsy and RP Gleason grade results were evaluated using chi-square analysis.
Results and limitations: No significant differences on RP were observed for proportions of patients having a HGG of 3 (35% vs 28%; p=0.50), 4 (32% vs 41%; p=0.51), and 5 (32% vs 31%; p=0.61) for the MR-GB and TRUSBx cohort, respectively. MR-GB showed an exact performance with RP for overall HGG: 88% (30 of 34); for TRUS-GB it was 55% (35 of 64; p=0.001). In the MR-GB cohort, an exact performance with HGG 3 was 100% (12 of 12); for HGG 4, 91% (10 of 11); and for HGG 5, 73% (8 of 11). The corresponding performance rates for TRUSBx were 94% (17 of 18; p=0.41), 46% (12 of 26; p=0.02), and 30% (6 of 20; p=0.01), respectively.
Conclusions: This study shows prospectively that DWI-directed MR-GBs significantly improve pretreatment risk stratification by obtaining biopsies that are representative of true Gleason grade.
Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Re: Thomas Hambrock, Caroline Hoeks, Christina Hulsbergen-van de Kaa, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:177-84.Eur Urol. 2012 May;61(5):e52. doi: 10.1016/j.eururo.2012.02.024. Epub 2012 Feb 18. Eur Urol. 2012. PMID: 22365282 No abstract available.
-
Words of wisdom. Re: Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort.Eur Urol. 2012 Oct;62(4):731-2. doi: 10.1016/j.eururo.2012.07.019. Eur Urol. 2012. PMID: 22939422 No abstract available.
Similar articles
-
Multiparametric MRI in detection and staging of prostate cancer.Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review.
-
Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the assessment of prostate cancer aggressiveness.Acta Radiol. 2017 Feb;58(2):232-239. doi: 10.1177/0284185116639764. Epub 2016 Jul 19. Acta Radiol. 2017. PMID: 27055916
-
Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies.Eur Urol. 2015 Oct;68(4):713-20. doi: 10.1016/j.eururo.2015.06.008. Epub 2015 Jun 23. Eur Urol. 2015. PMID: 26116294 Clinical Trial.
-
Magnetic resonance imaging‑directed biopsy improves the prediction of prostate cancer aggressiveness compared with a 12‑core transrectal ultrasound‑guided prostate biopsy.Mol Med Rep. 2014 May;9(5):1989-97. doi: 10.3892/mmr.2014.1994. Epub 2014 Feb 28. Mol Med Rep. 2014. PMID: 24584266
-
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.Health Technol Assess. 2013 May;17(20):vii-xix, 1-281. doi: 10.3310/hta17200. Health Technol Assess. 2013. PMID: 23697373 Free PMC article. Review.
Cited by
-
Prostate imaging-reporting and data system version 2 has improved biopsy tumor grade accuracy: a single, tertiary institutional experience.Abdom Radiol (NY). 2023 Jul;48(7):2370-2378. doi: 10.1007/s00261-023-03917-x. Epub 2023 Apr 26. Abdom Radiol (NY). 2023. PMID: 37099184
-
Simplified PI-RADS (S-PI-RADS) for biparametric MRI to detect and manage prostate cancer: What urologists need to know.Turk J Urol. 2021 May;47(3):175-182. doi: 10.5152/tud.2021.21004. Turk J Urol. 2021. PMID: 35929870 Free PMC article.
-
Prediction of prostate cancer grade using fractal analysis of perfusion MRI: retrospective proof-of-principle study.Eur Radiol. 2022 May;32(5):3236-3247. doi: 10.1007/s00330-021-08394-8. Epub 2021 Dec 16. Eur Radiol. 2022. PMID: 34913991 Free PMC article.
-
MRI grading for the prediction of prostate cancer aggressiveness.Eur Radiol. 2022 Apr;32(4):2351-2359. doi: 10.1007/s00330-021-08332-8. Epub 2021 Nov 8. Eur Radiol. 2022. PMID: 34748064 Free PMC article.
-
Multiparametric Prostate MRI in Biopsy-Naïve Men: A Prospective Evaluation of Performance and Biopsy Strategies.Front Oncol. 2021 Oct 14;11:745657. doi: 10.3389/fonc.2021.745657. eCollection 2021. Front Oncol. 2021. PMID: 34722302 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical